HorStem

RSS

equine umbilical cord mesenchymal stem cells

Authorised
This medicine is authorised for use in the European Union.

Overview

HorStem is a veterinary medicine used to treat lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses. It contains the active substance equine umbilical cord mesenchymal stem cells. These are stem cells taken from the umbilical cord of donor horses when a foal is born and grown in a laboratory to increase their numbers. Stem cells can develop into other types of cells.

This EPAR was last updated on 10/09/2019

Authorisation details

Product details
Name
HorStem
Agency product number
EMEA/V/C/004265
Active substance
equine umbilical cord mesenchymal stem cells
International non-proprietary name (INN) or common name
equine umbilical cord mesenchymal stem cells
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QM09AX
Publication details
Marketing-authorisation holder
EquiCord-Ymas S.L.
Date of issue of marketing authorisation valid throughout the European Union
19/06/2019
Contact address

103-D Loeches
Poligono Industrial Ventorro del Cano
Alcorcón
28925 Madrid
Spain

Product information

19/06/2019 HorStem - EMEA/V/C/004265 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM

Therapeutic indication

Reduction of lameness associated with mild to moderate degenerative joint disease (osteoarthritis) in horses.

Assessment history

How useful was this page?

Add your rating